SCHEMBL2391240

SCHEMBL2391240

NC(=O)c1cc(Nc2ccc(F)cc2)c(Nc2ccc(F)cc2)cc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 1/20 0.50
PRKD3 O94806 1/20 0.50
EGFR P00533 1/20 0.50
PRKCG P05129 1/20 0.50
PRKCB P05771 1/20 0.50
MAPT P10636 1/20 0.50
SRC P12931 1/20 0.50
PRKCA P17252 1/20 0.50
PRKCH P24723 1/20 0.50
PRKCI P41743 1/20 0.50
PRKCE Q02156 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCZ Q05513 1/20 0.50
PRKCD Q05655 1/20 0.50
PRKD1 Q15139 1/20 0.50
SIRT2 Q8IXJ6 8/20 0.45
CSF1R P07333 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9409104 0.89 SIRT2 (0.52) MEN1KMT2ATDP1ALDH1A1PRKD3
SCHEMBL8834266 0.83 DHODH (0.53) MEN1KMT2ATDP1ALDH1A1PRKD3
SCHEMBL9409036 0.83 PRKD3 (0.51) MEN1KMT2ATDP1ALDH1A1PRKD3
SCHEMBL27389993 0.82 SIRT2 (0.67) ALDH1A1SIRT2MAPK9MAPK10AGTR1
SCHEMBL9409101 0.81 MAPT (0.54) MEN1KMT2ATDP1ALDH1A1EGFR
SCHEMBL2723037 0.81 SIRT2 (0.58) ALDH1A1MAPTSIRT2JAK2
SCHEMBL9409031 0.81 LMNA (0.61) MEN1KMT2APRKD3SIRT2CSF1R
SCHEMBL9409154 0.80 AKR1C3 (0.55) MEN1KMT2AALDH1A1MAPTSIRT2
SCHEMBL1415570 0.79 MAPT (0.56) MEN1KMT2ATDP1ALDH1A1PRKD3
SCHEMBL8834288 0.79 MAPT (0.51) MEN1KMT2ATDP1ALDH1A1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0600832-A1 Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors CIBA-GEIGY AG (CH) 1994-06-08 EP claimed
JP-7076562-A None JP disclosed
EP-2373329-A2 USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION The Regents of the University of California (US) 2011-10-12 EP disclosed
US-20110236349-A1 Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-09-29 US disclosed
WO-2010123527-A2 USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-28 WO disclosed
JP-H0776562-A DIAMINOBENZOIC ACID DERIVATIVE CIBA GEIGY AG 1995-03-20 JP disclosed
EP-0600832-A1 Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors CIBA-GEIGY AG (CH) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110236349-A1 Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection EGFR, HDGF, HGF MEN1 1955/4885KMT2A 4260/4885TDP1 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.